혈소판 감소증 : 신규 요법, 미충족 요구 및 TPP 인사이트 보고서(2026년)

Thrombocytopenia Emerging Therapy and TPP Insights

Thelansis's "Thrombocytopenia Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Thrombocytopenia Overview

Thrombocytopenia is a reduction in platelet count that can arise from impaired marrow production, increased immune or nonimmune destruction, consumption, dilution, or splenic sequestration. Clinical significance varies with cause and severity; severe thrombocytopenia can cause petechiae, mucosal bleeding, or hemorrhage. Management is cause-specific and may include treating infection or drug triggers, corticosteroids or immunoglobulin for immune thrombocytopenia, platelet transfusion for selected bleeding settings, and therapy for underlying marrow or systemic disorders. Thrombopoietin receptor agonists, including romiplostim, eltrombopag, and avatrombopag, are established options in chronic immune thrombocytopenia and selected settings, but are not universal treatments for thrombocytopenia. Development is expanding toward improved platelet production, immune modulation, and therapies for chemotherapy-induced thrombocytopenia. Key needs include durable responses and safer targeted care.

Key Highlights

• In Germany, the prevalent Thrombocytopenia population is projected to increase from 145,075 in 2025 to 148,284 by 2035.
• Thrombocytopenia is characterized by low platelet counts, increasing the risk of bleeding and associated complications.
• Disease burden remains significant, particularly in patients with chronic or treatment-induced thrombocytopenia.
• Significant unmet need remains for therapies that provide sustained platelet recovery with improved safety.

Market Overview

• The France Thrombocytopenia market is projected to grow from $95M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing adoption of thrombopoietin receptor agonists and targeted therapies
• Improved diagnosis and management of chronic thrombocytopenia
• Future growth will depend on therapies that offer durable platelet response and reduced bleeding risk.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Qilu Pharmaceutical Co., Ltd.
• Gliknik Inc.
• Sobi, Inc.
• Sanofi
• Incyte Corporation
• Jian Zhu
• Nuvig Therapeutics, Inc.
• Eli Lilly and Company
• Dizal Pharmaceuticals
• Shanghai Escugen Biotechnology Co., Ltd.
• Argenx
• CASI Pharmaceuticals, Inc.
• Amgen
• Novartis Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Clover Biopharmaceuticals, Inc.
• Hutchmed
• Kedrion S.p.A.
• Takeda
• Keymed Biosciences Co., Ltd.
• Oscotec Inc.
• Alpine Immune Sciences, Inc.
• Ouro Medicines
• Chugai Pharmaceutical
• Celgene

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)